Impact of obesity on the efficacy of ustekinumab in Japanese patients with psoriasis: a retrospective cohort study of 111 patients

Archives of Dermatological Research

Volumn 306, Issue 10, 2014, Pages 921-925

  Yanaba, Koichi ^a   Umezawa, Yoshinori ^a   Ito, Toshihiro ^a   Hayashi, Mitsuha ^a   Kikuchi, Sota ^a   Fukuchi, Osamu ^a   Saeki, Hidehisa ^b   Nakagawa, Hidemi ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

Body mass index; Obesity; Psoriasis; Psoriasis area and severity index; Ustekinumab

Indexed keywords

USTEKINUMAB; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; BODY MASS; BODY WEIGHT; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OBESITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSORIASIS; PSORIASIS AREA AND SEVERITY INDEX; RETROSPECTIVE STUDY; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; ETHNOLOGY; IMMUNOLOGY; JAPAN; MIDDLE AGED; PATHOPHYSIOLOGY; PATIENT SELECTION; TIME; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ASIAN CONTINENTAL ANCESTRY GROUP; BODY MASS INDEX; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; JAPAN; MALE; MIDDLE AGED; OBESITY; PATIENT SELECTION; PSORIASIS; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84920964573     PISSN: 03403696     EISSN: 1432069X     Source Type: Journal    
DOI: 10.1007/s00403-014-1495-1     Document Type: Article

References (25)

1. Driessen RJ, Boezeman JB, van de Kerkhof PC, de Jong EM (2009) Three-year registry data on biological treatment for psoriasis: the influence of patient characteristics on treatment outcome. Br J Dermatol 160:670–675
2. Flegal KM, Carroll MD, Kit BK, Ogden CL (2012) Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999–2010. JAMA 307:491–497
3. Gisondi P, Del Giglio M, Di Francesco V, Zamboni M, Girolomoni G (2008) Weight loss improves the response of obese patients with moderate-to-severe chronic plaque psoriasis to low-dose cyclosporine therapy: a randomized, controlled, investigator-blinded clinical trial. Am J Clin Nutr 88:1242–1247
4. Griffiths CE, Strober BE, van de Kerkhof P et al (2010) Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med 362:118–128
5. Hossler EW, Wood GC, Still CD, Mowad CM, Maroon MS (2013) The effect of weight loss surgery on the severity of psoriasis. Br J Dermatol 168:660–661
6. Iannone F, Fanizzi R, Scioscia C, Anelli MG, Lapadula G (2013) Body mass does not affect the remission of psoriatic arthritis patients on anti-TNF-α therapy. Scand J Rheumatol 42:41–44
7. Igarashi A, Kato T, Kato M, Song M, Nakagawa H (2012) Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: long-term results from a phase 2/3 clinical trial. J Dermatol Sci 39:242–252
8. Jensen P, Zachariae C, Christensen R et al (2013) Effect of weight loss on the severity of psoriasis: a randomized clinical study. JAMA Dermatol 149:795–801
9. Lafuente-Urrez RF, Perez-Pelegay J (2014) Impact of obesity on the effectiveness of adalimumab for the treatment of psoriasis: a retrospective study of 30 patients in daily practice. Eur J Dermatol 24:217–223
10. Lebwohl M, Yeilding N, Szapary P et al (2010) Impact of weight on the efficacy and safety of ustekinumab in patients with moderate to severe psoriasis: rationale for dosing recommendations. J Am Acad Dermatol 63:571–579
11. Leonardi CL, Kimball AB, Papp KA et al (2008) Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 371:1665–1674
12. Lindegard B (1986) Diseases associated with psoriasis in a general population of 159,200 middle-aged, urban, native Swedes. Dermatologica 172:298–304
13. Naldi L, Addis A, Chimenti S et al (2008) Impact of body mass index and obesity on clinical response to systemic treatment for psoriasis. Evidence from the psocare project. Dermatology 217:365–373
14. Naldi L, Chatenoud L, Linder D et al (2005) Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study. J Invest Dermatol 125:61–67
15. Naldi L, Conti A, Cazzaniga S et al (2014) Diet and physical exercise in psoriasis: a randomized controlled trial. Br J Dermatol 170:634–642
16. Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB, Gelfand JM (2006) Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol 55:829–835
17. Nestle FO, Kaplan DH, Barker J (2009) Psoriasis. N Engl J Med 361:496–509
18. Papp KA, Langley RG, Lebwohl M et al (2008) Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 371:1675–1684
19. Schon MP, Boehncke WH (2005) Psoriasis. N Engl J Med 352:1899–1912
20. Shoelson SE, Lee J, Goldfine AB (2006) Inflammation and insulin resistance. J Clin Invest 116:1793–1801
21. Sumarac-Dumanovic M, Stevanovic D, Ljubic A et al (2009) Increased activity of interleukin-23/interleukin-17 proinflammatory axis in obese women. Int J Obes (Lond) 33:151–156
22. Tanaka S, Isoda F, Ishihara Y, Kimura M, Yamakawa T (2001) T lymphopaenia in relation to body mass index and TNF-α in human obesity: adequate weight reduction can be corrective. Clin Endocrinol (Oxf) 54:347–354
23. Wolk K, Mallbris L, Larsson P, Rosenblad A, Vingard E, Stahle M (2009) Excessive body weight and smoking associates with a high risk of onset of plaque psoriasis. Acta Derm Venereol 89:492–497
24. Yip SY (1984) The prevalence of psoriasis in the Mongoloid race. J Am Acad Dermatol 10:965–968
25. Zhu Y, Hu C, Lu M et al (2009) Population pharmacokinetic modeling of ustekinumab, a human monoclonal antibody targeting IL-12/23p40, in patients with moderate to severe plaque psoriasis. J Clin Pharmacol 49:162–175